Vaccines-2013 - OMICS Group

Recommendations

Info

Atefeh Shahbazi, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAProduction of nano-dendrimer containing HPV E 16d candidate vaccine and evaluation ofits immune responses in laboratory murine modelAtefeh ShahbaziPasteur Institute Tehran, IranCervical cancer is the second most common cancer in women worldwide. More than 99% of cervical cancers contain humanpapillomavirus (HPV) and HPV type 16 is the most common type in all countries. Papillomavirus-induced carcinogenesis ismainly related to two proteins E6 and E7 that are consistently expressed in HPV positive cervical carcinomas and are consideredsubstantially for therapeutic implications.Although the size of these proteins is small, they can attach to the regulatory proteins in host cells, eliminate cell-mediatedimmunity, and causes malignancy in the target tissue. Up to now, different methods have been used for production of therapeuticvaccines against human papillomavirus. These vaccines have some advantages and disadvantages.Today, researchers are seeking for carriers that can be loaded with vaccines and enhance the therapeutic effectiveness of thevaccine, so they have gone into production of dendrimers and nanotechnology.Due to their interesting abilities for carrying DNA, passing through the membrane and their appropriate size, dendrimershave been used extensively in vaccine delivery. In terms of size, shape, length and functional surface groups, nano-dendrimersare very similar. They can place the molecules among their branches and protect them against external factors and release themin target tissues.In this study, nano-dendrimer based E7d protein as a vaccine candidate was made and then at the dose of 10mg wasadministered to the experimental groups. Two groups were vaccinated with Ed proteins; frond and alum adjutant and controlswere injected with PBS buffer and dendrimer.Mice were vaccinated subcutaneously three times at two weeks interval. Two weeks after the last injection the immuneresponses were evaluated. Lymphocyte proliferative responses by BrdU method and the cytokines IL-4, IFN-g, and total antibodyIgG1, IgG2a were evaluated with ELISA. Finally, the results are shown that dendrimer nano vaccine candidate based on E7d -protein provoke the cellular and humeral immune responses and could be a good candidate for study in humans.Keywords: Human papillomavirus, E7d protein.ghazal.shahbazii@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 142
Birhanu Hurisa et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAProduction of cell culture based anti-rabies vaccine in EthiopiaBirhanu Hurisa 1 , Abebe Mengesha 1 , Bethlehem Newayesilassie 1 , Sisay Kerga 1 , Gezahegn Kebede 1 , Denis Bankovisky 2 , Arthem Metlin 3and Kelbessa Urga 11Ethiopian Health and Nutrition Research Institute, Ethiopia2Pokrov Plant of Biologics, Russian Federation3Federal Centre for Animal Health, Russian FederationPrevention and control of rabies in the world will require international efforts to increase the availability and use of high qualitycell-culture rabies vaccines for use in human and veterinary. An important aspect of activities to ensure such availability istransfer of technologies to developing countries for production of these vaccines. Methods for rabies virus manipulation havechanged fundamentally from random attenuation to defined modifications. In 2001, WHO issued a resolution for the completereplacement of nerve tissue vaccines by 2006 with cell culture rabies vaccines. However, sheep brain derived Fermi type rabiesvaccine is still being manufactured and utilized for the majority of exposed patients in Ethiopia. Therefore, production of asafer and effective cell culture based anti-rabies vaccine is needed. Currently the Ethiopian government has heavily invested inupgrading the facilities required to produce a rabies vaccine in keeping with WHO recommendation. Rabies virus suspensionswere obtained from Vero cells cultivated on roller bottles after infection with the Pasteur virus strain (PV) and Evelyn RokitnikiAbelseth (ERA). Initially the titer of the obtained virus and multiplicity of infection of the viruses had to be optimized; thereforein rabies virus infected with 0.1, 0.01 and 0.001 cultures were incubated at 37 °C in 5% CO2 for 48, 72 and 96. Higher virus yieldswere obtained when cells were infected with 0.001 ERA virus and 0.01 PV virus incubated for 96 hr and 72 hr respectively.Keywords: ERA; PV; Fermi; cell culture; multiplicity of infection.bhurrish@yahoo.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 143
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74:
Young Research ForumSession ChairPe
Page 75 and 76:
Humberto Hernandez et al., J Vaccin
Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90:
Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 117 and 118: 111 th OMICS Group Conference3 rd I
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 141: 111 th OMICS Group Conference3 rd I
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?